Valbenatsiin

Valbenatsiin, known chemically as valbenazine, is a prescription medication used to treat tardive dyskinesia in adults. It is a selective inhibitor of vesicular monoamine transporter 2 (VMAT2), a protein that helps store and release dopamine in nerve terminals. By reducing VMAT2 activity, valbenatsiin lowers excessive dopamine release, which can lessen involuntary movements associated with long-term antipsychotic treatment.

The drug is taken by mouth and is typically prescribed as a once-daily dose, with adjustments made by the clinician based on response and tolerability. Dosing schedules may be started at a lower level and increased as needed. Valbenatsiin is usually continued for as long as tardive dyskinesia symptoms persist, under regular medical supervision. It may interact with other medicines that affect liver enzymes, particularly those inhibiting or inducing CYP3A4 or CYP2D6, which can alter valbenatsiin levels. Dose adjustments or monitoring may be required when such drugs are used concomitantly.

Common side effects reported with valbenatsiin include somnolence, fatigue, dry mouth, and nausea. Less frequent effects can include headache, restlessness, or weight changes. Serious adverse events are uncommon but may occur; patients are advised to seek medical attention for any new or worsening symptoms, especially signs of neuroleptic malignant syndrome or severe movement disorders. Valbenatsiin is approved for tardive dyskinesia in several countries, with the United States FDA approval in 2017 under the brand name Ingrezza.